Clinical comparative studies have shown that compared with the XELOX plus sintilimab regimen alone, the combination of FZLZD and this regimen can significantly reduce traditional Chinese medicine symptom scores, lower tumor marker levels, and interleukin 6 levels in the treatment of advanced GC, and meaningfully improve health-related quality of life metrics. This evidence concerns the gene IL6 and neoplasm.